Brain PathologyNeurosciencePeer-reviewed journal article
Olfactory proteomics reveals the capacity of the HDAC1 inhibitor pyroxamide to halt the α-synuclein preformed fibrils-induced damage in nasal epithelial, microglial and dopaminergic neuronal cell lines
Paz Cartas‐CejudoiD, Marina De Miguel, Leire ExtramianaiD, Mercedes Lachén‐MontesiD, Silvia Romero-MurilloiD, Djordje O. GvericiD, Joaquín Fernández‐IrigoyeniD, Enrique SantamaríaiD
Abstract
Parkinsons disease (PD) is the second most common neurodegenerative disorder mainly characterized by the degeneration of dopaminergic neurons originating in the substantia nigra (SN) pars compacta and projecting to other brain regions, giving rise to motor and non-motor symptoms. Despite significant progress in understanding the molecular and cellular disruptions associated with PD, there remains an unmet clinical need for effective therapies. In this study, proteomic analysis of the olfactory tract (OT) in controls with no known neurological history (n=17) and PD subjects (n=21) revealed Lewy body disease (LBD) stage-dependent proteostatic impairment, accompanied by progressive modulation of the alpha-synuclein (-syn) functional interactome. Differential OT omic profiles (OMS) were used in a computational drug repurposing approach, reveling the HDAC1 inhibitor pyroxamide as one of the top drug candidates with in silico potential to restore altered OMS. To explore the potential therapeutic effects of pyroxamide, in vitro assays were performed using -syn preformed fibrils (PFFs). Pyroxamide treatment reduced -syn PFFs-induced toxicity in olfactory epithelial, microglial and dopaminergic neuronal cell lines, producing a protective effect against hydrogen peroxide-induced damage exclusively in brain-derived cell types. These findings confirm the suitability of omics profiles in drug repurposing workflows against PD, offering valuable insights into the potential of HDAC1 inhibitors in the therapeutic pipeline of PD. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=54 SRC="FIGDIR/small/679944v1_ufig1.gif" ALT="Figure 1"> View larger version (14K): org.highwire.dtl.DTLVardef@1e7a8e8org.highwire.dtl.DTLVardef@229c2org.highwire.dtl.DTLVardef@39f5corg.highwire.dtl.DTLVardef@1d35105_HPS_FORMAT_FIGEXP M_FIG C_FIG
- organism: human
- assay: proteomics
- research focus: drug response / drug discovery
- approach: statistical model
- Citations
- 0
- FWCI
- 0.00
- Field percentile
- top 34%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- DOPAL initiates αSynuclein-mediated impaired proteostasis in neuronal projections leading to enhanced vulnerability in Parkinson's disease.
Anna Masato, Nicoletta Plotegher, … Luigi Bubacco·bioRxiv·Jun 15, 2021
- In vivo Proximity & Spatial Proteomics with CRISPR Screening Identify STXBP1 as a Protective Modifier of a-synuclein Toxicity in Dopamine Neurons.
Daichi Shonai, Julie K. Kent, … Scott H. Soderling·bioRxiv·Jan 17, 2026
- A high-content imaging workflow to screen for molecules that reduce cellular uptake of α-synuclein preformed fibrils
Wolfgang Reintsch, Andrea I. Krahn, … Thomas M. Durcan·MethodsPeer-reviewed·May 5, 2026
- A 2D Fragment-Assisted Protein Mimetic Approach to Rescue α-Synuclein Aggregation Mediated Early and Post-Disease Parkinsons Phenotypes
S. Kumar, N. H. Stillman, … C. M. Donnelly·bioRxiv·Jul 11, 2022
- Neuronal hemoglobin induces loss of dopaminergic neurons in mouse Substantia nigra, cognitive deficits and cleavage of endogenous α-synuclein.
Santulli Chiara, Carlotta Bon, … Stefano Gustincich·bioRxiv·Oct 13, 2021
- PODXL regulates the neuronal entry of α-synuclein aggregates
Sandesh Neupane, Lea Šustić, … Adriano Aguzzi·bioRxiv·Oct 21, 2026